<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585766</url>
  </required_header>
  <id_info>
    <org_study_id>CD-IA-MEDI-551-1102</org_study_id>
    <nct_id>NCT01585766</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ascending intravenous
      (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of
      multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, multinational, randomized, blinded, placebo-controlled,
      dose-escalation study to evaluate the safety and tolerability of IV and SC doses of MEDI-551
      in adult subjects with relapsing forms of MS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Day 1 to Day 169</time_frame>
    <description>To evaluate the safety and tolerability of ascending IV and SC doses of MEDI-551 in adult subjects with relapsing forms of MS through the assessment of treatment-emergent adverse events and serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI-551</measure>
    <time_frame>Day 1 to Day 169</time_frame>
    <description>To evaluate the pharmacokinetics (PK) of MEDI-551 in the subject population (including but not limited to Cmax, Tmax, T1/2, AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Effect of MEDI-551</measure>
    <time_frame>Day 1 to Day 169</time_frame>
    <description>To describe the pharmacodynamic (PD) effects of MEDI-551 as measured by the change in B cell count from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of MEDI-551</measure>
    <time_frame>Day 1 to Day 169</time_frame>
    <description>To evaluate the immunogenicity (IM) of MEDI-551 in the subject population</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Multiple Sclerosis, Relapsing Forms</condition>
  <arm_group>
    <arm_group_label>MEDI-551 Dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Level 1 x 2 MEDI-551 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 Dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Level 2 x 2 MEDI-551 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 Dosage 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Level 3 x 1 MEDI-551 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 Dosage 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Level 4 x 1 MEDI-551 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-551 Dosage 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage Level 5 x 2 MEDI-551 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC x 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551 IV</intervention_name>
    <description>Associated Dosage Level x 2 MEDI-551 IV</description>
    <arm_group_label>MEDI-551 Dosage 1</arm_group_label>
    <arm_group_label>MEDI-551 Dosage 2</arm_group_label>
    <arm_group_label>MEDI-551 Dosage 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-551 SC</intervention_name>
    <description>Associated Dosage Level X 1 MEDI-551 SC</description>
    <arm_group_label>MEDI-551 Dosage 3</arm_group_label>
    <arm_group_label>MEDI-551 Dosage 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Placebo IV x 2</description>
    <arm_group_label>Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Placebo SC x 1</description>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed relapsing form of MS (ie, RRMS, SPMS, PRMS, or CIS) according to revised
             2010 McDonald criteria and MRI brain lesions consistent with MS on screening

          -  At least 1 documented relapse within the past 3 years prior to screening

          -  EDSS between 0.0 and 6.5 at screening

          -  Have no more than 20 Gd-enhancing T1 brain lesions detected by cranial MRI scan

        Exclusion Criteria:

          -  Subjects with impaired renal function

          -  Major surgery within 8 weeks of the screening visit

          -  Subjects who are unable to undergo cranial MRI scan

          -  A history of hypersensitivity to Gd-containing MRI contrast agents

          -  Has received within 1 year prior to screening: monoclonal antibodies, experimental
             B-cell depleting agents, or treatment with natalizumab (Tysabri) for greater than 3
             months

          -  Receiving monthly methylprednisone or equivalent glucocorticoid for disease
             modification of a relapsing form of MS

          -  Known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent
             antihistamine, methylprednisolone or equivalent glucocorticoid, or to any component of
             the investigational drug

          -  Diagnosis of PPMS, neuromyelitis optica, or other non-MS variant of neuro-inflammatory
             or demyelinating diseases

          -  Any history of opportunistic infection or the presence of active infection within two
             months prior to screening or any herpes zoster infection that has not resolved within
             12 weeks prior to screening

          -  Any clinically significant findings during the screening phase, including physical,
             neurological, laboratory, or ECG examination as per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Flor</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAb, B cell, depletion, RMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 13, 2017</submitted>
    <returned>January 23, 2018</returned>
    <submitted>February 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

